HomeCompareCFRX vs PLD

CFRX vs PLD: Dividend Comparison 2026

CFRX yields 4000.00% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CFRX wins by $7175340620749.96M in total portfolio value
10 years
CFRX
CFRX
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full CFRX calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — CFRX vs PLD

📍 CFRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFRXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFRX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CFRX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFRX
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, CFRX beats the other by $5,813,155,604,214,122,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFRX + PLD for your $10,000?

CFRX: 50%PLD: 50%
100% PLD50/50100% CFRX
Portfolio after 10yr
$3587670310380.89M
Annual income
$3,419,503,296,601,293,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CFRX
Analyst Ratings
1
Strong
1
Buy
3
Hold
Consensus: Hold
Altman Z
-60.9
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFRX buys
0
PLD buys
0
No recent congressional trades found for CFRX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFRXPLD
Forward yield4000.00%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$7175340620755.87M$5.91M
Annual income after 10y$6,839,006,593,197,835,000.00$4,750,725.19
Total dividends collected$7152397773804.84M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: CFRX vs PLD ($10,000, DRIP)

YearCFRX PortfolioCFRX Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$410,700$400,000.00$11,241$540.96+$399.5KCFRX
2$15,792,720$15,353,271.03$13,019$991.13+$15.78MCFRX
3$568,657,142$551,758,931.89$15,801$1,870.97+$568.64MCFRX
4$19,176,207,860$18,567,744,718.20$20,609$3,701.21+$19176.19MCFRX
5$605,696,028,890$585,177,486,479.73$29,919$7,867.97+$605696.00MCFRX
6$17,922,210,653,594$17,274,115,902,681.27$50,631$18,617.74+$17922210.60MCFRX
7$496,869,793,504,300$477,693,028,104,954.00$105,528$51,352.20+$496869793.40MCFRX
8$12,908,672,105,251,704$12,377,021,426,202,104.00$287,364$174,449.42+$12908672104.96MCFRX
9$314,330,866,876,668,540$300,518,587,724,049,200.00$1,081,760$774,280.77+$314330866875.59MCFRX
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$5,908,209$4,750,725.19+$7175340620749.96MCFRX

CFRX vs PLD: Complete Analysis 2026

CFRXStock

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Full CFRX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CFRX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFRX vs SCHDCFRX vs JEPICFRX vs OCFRX vs KOCFRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.